CLMT: $347 million of Q3 Adjusted EBITDA as specialty strength and renewables growth accelerated deleveraging

Calumet, Inc. reported Q3 2026 Adjusted EBITDA of $347 million, driven by specialty products and Montana Renewables. The company continued deleveraging and expects future growth from specialty supply constraints and MaxSAF expansion, according to management.

Original reporting
Published Nov 6, 2026, 4:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CLMT: $347 million of Q3 Adjusted EBITDA as specialty strength and renewables growth accelerated deleveraging — source image
Decision brief

The 30-second read

$CLMTBullishMed
01

Why it matters

The earnings beat provides a fresh catalyst for the stock, with potential upside in the near term.

02

Market read

First‑time disclosure of Q3 EBITDA offers a trading opportunity for CLMT.

03

What to watch

Potential supply constraints in specialty products could cap future upside.

Relevance 7/10Novelty 7/10Timing: post‑market release

Background

Calumet Inc. released its Q3 2026 earnings summary, highlighting EBITDA and renewables growth.

Company-level read

Ticker impact

$CLMTBullishHigh confidence
Context

Q3 2026 Adjusted EBITDA of $347 million reported, indicating strong specialty and renewables performance.

Expected impact

likely upside as investors price in stronger-than-expected earnings

Evidence & confidence

The disclosed EBITDA figure is new and material for a mid‑cap industrial company, providing a clear catalyst for short‑term trading.

Market effects

Strength in specialty chemicals and renewables may lift peers in the industrial sector.

U.S. industrial equities could see modest gains.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

If the EBITDA growth is driven by one‑off items, the rally could be short‑lived.

Key entities

  • Calumet Inc.

    U.S. industrial chemicals and renewables producer.

Related articles

$CLMTHighAI 8/10

Calumet (CLMT) Q3 2026 Earnings Call Transcript

Calumet (CLMT) reported Q3 2026 earnings with adjusted EBITDA of $347.2M, up from $92.5M in Q3 2025. Net income was $273.3M, down from $313.4M YoY. The company retired $265M in debt, reducing annual interest by $26M. Specialty Products and Solutions EBITDA was $248.1M, while Montana Renewables EBITDA was $110.6M. Management highlighted debt reduction, strategic restructuring, and plans to increase sustainable aviation fuel production.

$CLMTMed

What Calumet (CLMT) Said on Its Q3 Earnings Call

Calumet (CLMT) reported Q3 earnings, highlighting a completed turnaround at its Shreveport facility and progress on Montana Renewables' expansion. Adjusted EBITDA for Montana Renewables was $110.6M, with CMR contributing $40.8M. The company plans to increase sustainable aviation fuel production, with a path to 200M gallons annually by 2028. Debt reduction remains a priority, with $175M in 2028 notes outstanding.

$CLMTHighAI 8/10

Calumet Reports Third Quarter 2026 Results

Calumet, Inc. /DE (CLMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calumet Reports Third Quarter 2026 Results • Third Quarter 2026 net income of $273.3 million, or basic earnings per common share of $2.91 • Third Quarter 2026 Adjusted EBITDA with Tax Attributes of $347.2 million • Accelerated deleveraging continues with approximatel

$CLMTHigh

CALUMET ($CLMT) Releases Q3 2026 Earnings

CALUMET ($CLMT) reported Q3 2026 earnings of $4.65 per share, exceeding estimates by $2.97. Revenue was $1.68 billion, surpassing expectations by $312.43 million. Insiders sold shares, while hedge funds had mixed activity, with some increasing and others decreasing their positions.